| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/20/2003 | WO2003013486A1 The treatment of lipodystrophy |
| 02/20/2003 | WO2003013474A1 Nanoparticulate formulations of fenofibrate |
| 02/20/2003 | WO2003013440A2 Treatment and prevention of heat shock protein-associated diseases and conditions |
| 02/20/2003 | WO2003013438A2 Nutrient therapy for immuno-compromised patients |
| 02/20/2003 | WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace |
| 02/20/2003 | WO2003013277A1 Chitosan-containing powder |
| 02/20/2003 | WO2003013276A1 Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level |
| 02/20/2003 | WO2003013275A1 Composition for lowering blood cholesterol |
| 02/20/2003 | WO2002102794A3 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 02/20/2003 | WO2002096927A3 Ribozyme based treatment of female reproductive diseases |
| 02/20/2003 | WO2002094200A3 Pulmonary administration of chemically modified insulin |
| 02/20/2003 | WO2002085368A3 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/20/2003 | WO2002074228A3 Pharmaceutical composition for the treatment of diabetes comprising a 5-phenoxyalkal-2,4-thiazolidinedione derivative and a compound that stimulates insulin secretion |
| 02/20/2003 | WO2002070016A8 Catecholate beta-lactam conjugates, method for producing the same and the use thereof |
| 02/20/2003 | WO2002068387A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/20/2003 | WO2002066505A3 Gmg-3, gmg-4, and gmg-6 polynucleotides and polypeptides and uses thereof |
| 02/20/2003 | WO2002065979A3 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
| 02/20/2003 | WO2002064126A3 Method of treating of demyelinating diseases or conditions |
| 02/20/2003 | WO2002064109A3 Mucoadhesive pharmaceutical formulations |
| 02/20/2003 | WO2002053090A3 Medicinal association of a biguanine (metformin) and arginine |
| 02/20/2003 | WO2002049993A3 High affinity small molecule c5a receptor modulators |
| 02/20/2003 | WO2002032842A9 Compounds with high monoamine transporter affinity |
| 02/20/2003 | WO2002030882A9 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002030860A9 Ketone compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002029088A9 Highly expressible genes |
| 02/20/2003 | WO2002024635A3 Aminoalcohol derivatives |
| 02/20/2003 | WO2002019842A2 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
| 02/20/2003 | WO2002014368A8 Proteins and nucleic acids encoding the same |
| 02/20/2003 | WO2001072325A9 Methods of blocking tissue destruction by autoreactive t cells |
| 02/20/2003 | WO2001056547B1 Preparation of aqueous clear solution dosage forms with bile acids |
| 02/20/2003 | US20030036652 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines |
| 02/20/2003 | US20030036651 As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases |
| 02/20/2003 | US20030036558 Useful in the treatment of chronic complications arising from diabetes, such as neuropathy; may also contain an angiotensin converting enzyme inhibitor. |
| 02/20/2003 | US20030036546 Administering an opioidergic composition, such as opiate antagonist, an opiate agonist and a combination thereof. |
| 02/20/2003 | US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease. |
| 02/20/2003 | US20030036526 Activating a signaling cascade comprising, introducing leptin and/or a cytokine to a receptor complex comprising gp 130, to genes in neuro- endocrine cells or cells of neuro-endocrine origin. |
| 02/20/2003 | US20030036513 Reducing the effective dose of an anti-cancer agent by administering a redox clamping agent, especially Mesna, in conjunction with an anti-cancer agent. |
| 02/20/2003 | US20030036512 A neurotrophic factor, such as brain-derived neurotrophic factor; treating leptin resistance caused hypertension, sterility, obesity, glucose metabolic abnormality, ischemic disease and growth hormone insufficiency |
| 02/20/2003 | US20030036507 Urocortin-III and uses thereof |
| 02/20/2003 | US20030036504 Modululation of both fasting and postprandial lipid levels. |
| 02/20/2003 | US20030035832 Compression of drug and adjuvant |
| 02/20/2003 | US20030035799 Glycosylated antibody |
| 02/20/2003 | CA2457624A1 Nutrient therapy for immuno-compromised patients |
| 02/20/2003 | CA2456964A1 Melanin-concentrating hormone antagonists |
| 02/20/2003 | CA2456939A1 Carbonic anhydrase inhibitors |
| 02/20/2003 | CA2456720A1 Asymmetric synthesis of kavalactones |
| 02/20/2003 | CA2456713A1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| 02/20/2003 | CA2456607A1 Uses of mammalian cytokine; related reagents |
| 02/20/2003 | CA2456599A1 Spiro compounds |
| 02/20/2003 | CA2456549A1 The treatment of lipodystrophy |
| 02/20/2003 | CA2456288A1 Fatty acid compounds, preparation and uses thereof |
| 02/20/2003 | CA2456250A1 Arylsulfonyl derivatives with 5-ht6 receptor affinity |
| 02/20/2003 | CA2456159A1 Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level |
| 02/20/2003 | CA2456124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 02/20/2003 | CA2456103A1 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 02/20/2003 | CA2456030A1 Hypoglycemic agent |
| 02/20/2003 | CA2455761A1 Artichoke leaf extracts |
| 02/20/2003 | CA2455756A1 Use of thrombin-derived peptides for the therapy of chronic dermal ulcers |
| 02/20/2003 | CA2455498A1 Antisense modulation of apolipoprotein(a) expression |
| 02/20/2003 | CA2455336A1 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | CA2454072A1 Crystalline forms of fluvastatin sodium |
| 02/20/2003 | CA2453995A1 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | CA2453884A1 Micronutrient phosphates as dietary and health supplements |
| 02/20/2003 | CA2453537A1 Therapeutic 1h-pyrido¬4,3-b|indoles |
| 02/20/2003 | CA2453219A1 Therapeutically useful tetracyclic ligands |
| 02/20/2003 | CA2451919A1 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 02/20/2003 | CA2419389A1 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof |
| 02/19/2003 | EP1284423A2 Adrenic acid (delta 7,10,13,16 docosatetraenoic acid ) receptor and uses thereof |
| 02/19/2003 | EP1284268A1 Thiazolidinedione derivative and its use as antidiabetic |
| 02/19/2003 | EP1284265A1 Benzothiophene derivatives and medicinal use thereof |
| 02/19/2003 | EP1284260A1 Tyrosine phosphatase inhibitors |
| 02/19/2003 | EP1284259A1 5,6- i TRANS /i -2-ALKYLVITAMIN D DERIVATIVES |
| 02/19/2003 | EP1284139A1 Novel fatty acid analogues for the treatment of fatty liver |
| 02/19/2003 | EP1283886A2 Intracellular signaling proteins |
| 02/19/2003 | EP1283848A2 Protein complexes and assays for screening anti-cancer agents |
| 02/19/2003 | EP1283835A2 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 02/19/2003 | EP1283834A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283833A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283832A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283831A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/19/2003 | EP1283830A1 Para-amine substituted phenylamide glucokinase activators |
| 02/19/2003 | EP1283828A1 Novel polymorph v of torasemide |
| 02/19/2003 | EP1283827A2 Caspase inhibitors and uses thereof |
| 02/19/2003 | EP1283735A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 02/19/2003 | EP1283721A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/19/2003 | EP1283708A2 Use of biguanide derivatives for making a medicine having a wound healing effect |
| 02/19/2003 | EP1283682A2 Tryptophan source from plants and uses therefor |
| 02/19/2003 | EP1207878B1 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 02/19/2003 | EP1165559B1 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics |
| 02/19/2003 | EP1131327B1 Prostaglandin conjugates for treating or preventing bone diseases |
| 02/19/2003 | EP1119571B1 Tricyclic delta3-piperidines as alpha2-antagonists |
| 02/19/2003 | EP1115729B1 Phosphonic acid derivatives as inhibitors of ptp-1b |
| 02/19/2003 | EP1033131B1 Composition in the form of a drink having a delayed alcohol aversion effect |
| 02/19/2003 | EP1001788B1 Boron carbohydrate complexes and uses thereof |
| 02/19/2003 | EP0920429B1 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| 02/19/2003 | EP0868175B1 Nitric oxide (no) synthase inhibitor to prevent type ii diabetes |
| 02/19/2003 | CN1398300A Novel elongase gene and method for producing multiple-unsaturated fatty acids |
| 02/19/2003 | CN1398260A 二肽腈组织蛋白酶k抑制剂 Dipeptide nitrile cathepsin inhibitors k |
| 02/19/2003 | CN1398254A Vitamin D derivatives having substituents at 2 alpha position |
| 02/19/2003 | CN1397560A Process for extracting general platycodoside and platycoligenin D from platycodon root, its medical application and its Chinese medicine |